New drug tested for leukemia that returns after transplant
NCT ID NCT05506956
Summary
This small, early-stage study tested the safety of an experimental drug called flotetuzumab. It was given to a few adults with a type of blood cancer (AML) that had come back after they received a bone marrow transplant. The main goal was to see if the drug was safe and to find the right dose, while also checking if it helped control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.